Telix PharmaceuticalsTLX +6.76%50 PB Ratio is 8.89 as of Jun. 24, 2026, which is 46% below its 10-year median of 16.53. GuruFocus rates TLX with a GF Score™ of 50/100 and a GF Value™ of $27.71 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,233 Biotechnology companies, Telix Pharmaceuticals ranks worse than 82.16% on this metric.
The historical rank and industry rank for Telix Pharmaceuticals's PB Ratio or its related term are showing as below:
TLX'
s PB Ratio Range Over the Past 10 Years
Min: 2.72 Med: 16.53 Max: 1083.75
Current: 9.08
During the past 11 years, Telix Pharmaceuticals's highest PB Ratio was 1083.75. The lowest was 2.72. And the median was 16.53.
TLX's PB Ratio is ranked worse than 82.16% of 1233
companies
in the Biotechnology industry
Industry Median: 2.83
vs TLX: 9.08
During the past 12 months, Telix Pharmaceuticals's average Book Value Per Share Growth Rate was 10.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 93.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 109.70% per year.
During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of Telix Pharmaceuticals was 492.60% per year. The lowest was -67.70% per year. And the median was 6.90% per year.
Back to Basics: PB Ratio
Telix Pharmaceuticals (NAS:TLX) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Telix Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Telix Pharmaceuticals PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Telix Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Telix Pharmaceuticals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Telix Pharmaceuticals (TLX) has a PB Ratio of 8.89 as of Jun. 24, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Telix Pharmaceuticals and its competitors. This is 46% below median its historical median of 16.53. Over the past decade, Telix Pharmaceuticals' PB Ratio has ranged from 2.72 to 1,083.75. According to the industry distribution chart, Telix Pharmaceuticals ranks #1013 out of 1233 companies in the Biotechnology industry, placing it in the top 82.2%.
Is Telix Pharmaceuticals' PB Ratio too high?
Telix Pharmaceuticals' current PB Ratio of 8.89 is 46% below median its 10-year median of 16.53. Over the past 10 years, this metric has ranged from a low of 2.72 to a high of 1,083.75. The Biotechnology industry median PB Ratio is 2.83. Telix Pharmaceuticals' value of 8.89 is 214.1% above this industry median. Based on the distribution chart, Telix Pharmaceuticals ranks #1013 out of 1233 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Telix Pharmaceuticals has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Telix Pharmaceuticals' PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Telix Pharmaceuticals ranks #1013 out of 1233 companies for PB Ratio. This places Telix Pharmaceuticals in the lower half of its industry. The industry median PB Ratio is 2.83. Telix Pharmaceuticals' value of 8.89 is 214.1% above this benchmark. Historically, Telix Pharmaceuticals' own PB Ratio has ranged from 2.72 to 1,083.75 over the past decade. While the company's 10-year median is 16.53 vs. the industry median of 2.83, Telix Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.83, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Telix Pharmaceuticals's current PB Ratio of 8.89 is 214.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Telix Pharmaceuticals and its competitors. For the Biotechnology industry, the median PB Ratio is 2.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Telix Pharmaceuticals's current PB Ratio is 8.89, which is 46% below median its own 10-year median of 16.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Telix Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Telix Pharmaceuticals (TLX) is currently considered Possible Value Trap. The stock's GF Value™ is $27.71, compared to a current price of $10.90 — trading 60.7% below its estimated fair value. The current PB Ratio is 8.89, which is 46% below median its 10-year median of 16.53 and 214.1% above the Biotechnology industry median of 2.83. Telix Pharmaceuticals' overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Telix Pharmaceuticals (TLX), the current PB Ratio is 8.89 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Telix Pharmaceuticals (TLX) Overvalued in 2026?
Based on GuruFocus' analysis, Telix Pharmaceuticals stock appears to be undervalued.
The current stock price of $10.90 is trading 60.7% below its estimated GF Value™ of $27.71.
GuruFocus considers Telix Pharmaceuticals to be Possible Value Trap.
Key valuation signals for TLX:
PB Ratio: 8.89 (46% below median its 10-year median of 16.53)
GF Value™: $27.71 vs. price of $10.90 (60.7% below fair value)
Industry Position: 214.1% above the Biotechnology median (#1013 of 1233)
No single metric tells the full story. See the TLX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
50GF Score
Get the complete analysis for TLX
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TLX has been successfully added to your 
